Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, tumor-specific immunogene therapies for the treatment of cancer. He was previously Executive Director and Head of Immunology for Pfizer’s Vaccine Immunotherapeutics Research Unit in La Jolla, California, leading the immunology team providing expertise and immunoassays for Pfizer vaccine projects, program leader for an anti-IgE therapeutic vaccine for allergy/asthma, and a member of the leadership team. Prior to this he was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex in Cambridge (UK) developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.